Viewing Study NCT02870569

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:58 PM
Ignite Modification Date: 2026-02-25 @ 7:04 PM
Study NCT ID: NCT02870569
Status: COMPLETED
Last Update Posted: 2019-03-01
First Post: 2016-08-12
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Differentiated Thyroid Cancer View
Keywords: